Perrigo to review options for multiple sclerosis drug royalties

(Reuters) – Perrigo Company Plc, a maker of generic and over-the-counter drugs, said it will review strategic alternatives for the rights to the royalties from sales of its multiple sclerosis drug.

Dublin-based Perrigo has hired Morgan Stanley as its financial adviser to lead the review process for the drug, Tysabri, the company said in a statement on Thursday.

(Reporting By Aurindom Mukherjee in Bengaluru; Editing by Amrutha Gayathri)